Ivosidenib (IVO; AG-120) in IDH1-mutant newly-diagnosed acute myeloid leukemia (ND AML): Updated results from a phase 1 study.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Gail J. Roboz, Courtney Denton Dinardo, Eytan M. Stein, Stéphane de Botton, Alice S. Mims, Gabrielle T. Prince, Jessica K. Altman, Martha Lucia Arellano, Harry Paul Erba, Daniel Aaron Pollyea, Anthony Selwyn Stein, Justin M. Watts, Amir Tahmasb Fathi, Hagop M. Kantarjian, Martin S. Tallman, Bin Fan, Hua Liu, Bin Wu, Eyal C. Attar, Richard M. Stone
Institutions: Weill Cornell Medicine, The University of Texas MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, The Ohio State University Wexner Medical Center, Johns Hopkins Hospital, Northwestern University, Winship Cancer Institute, University of Alabama at Birmingham, University of Colorado Anschutz, City Of Hope National Medical Center, Sylvester Comprehensive Cancer Center, Massachusetts General Hospital, Agios Pharmaceuticals (United States), Dana-Farber Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2954597010